GeneHealth - Your precision medicine

Dilated Cardiomyopathy 1s

Disease Details

Family Health Simplified

Buy Membership

Description: Dilated cardiomyopathy (DCM) is a condition where the heart's ability to pump blood is decreased because the left ventricle is enlarged and weakened.
Type: Dilated cardiomyopathy 1S (DCM1S) is typically inherited in an autosomal dominant manner.
Signs And Symptoms: Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. Key signs and symptoms of dilated cardiomyopathy include:

- Breathlessness (dyspnea) during exertion or even at rest
- Reduced ability to exercise
- Fatigue
- Swelling (edema) in the legs, ankles, and feet
- Swelling of the abdomen (ascites)
- Chest pain or pressure
- Heart palpitations (irregular heartbeats)
- Dizziness, lightheadedness, or fainting (syncope)

These symptoms may vary in severity and can develop gradually or suddenly.
Prognosis: For dilated cardiomyopathy (DCM):

**Prognosis:** The prognosis for dilated cardiomyopathy varies widely depending on the severity of the condition, the patient's overall health, and their response to treatment. Some individuals experience stable disease for years, while others may have progressive worsening of heart function leading to heart failure.

**Nan:** The term "nan" does not apply to medical conditions and usually represents a placeholder for missing numeric data in datasets. If you need information on a specific aspect of dilated cardiomyopathy, please provide more context.
Onset: Dilated cardiomyopathy (DCM) is a condition where the heart's ability to pump blood is decreased because the left ventricle is enlarged and weakened. The onset of DCM can occur at any age, including in infancy. It may develop gradually over time, or symptoms can emerge suddenly. The exact timing can vary widely among individuals depending on the underlying cause.
Prevalence: Information on the prevalence of specific subtypes of genetic conditions, such as dilated cardiomyopathy 1S, may not be well-documented in the literature. Generally, dilated cardiomyopathy (DCM) affects roughly one in 250 individuals worldwide, but the prevalence of this particular genetic subtype (1S) is not specified. Further research and genetic screening data are often needed to determine more precise prevalence rates for specific subtypes.
Epidemiology: Epidemiology: Dilated cardiomyopathy (DCM) is a condition characterized by the enlargement and weakening of the heart's ventricles, impairing the heart's ability to pump blood efficiently. It affects individuals of all ages but is most commonly diagnosed in middle-aged adults. The prevalence of DCM is about 1 in 2,500 individuals, making it one of the more common types of cardiomyopathy. DCM can be idiopathic, familial, or result from other factors such as infections, toxins, or systemic diseases. It is slightly more common in men than in women.

Nan: No additional information is available.
Intractability: Dilated cardiomyopathy (DCM) can be challenging to manage, but it is not inherently intractable. Treatment options such as medications, lifestyle changes, and sometimes surgical interventions can help manage symptoms and improve quality of life. However, in severe cases where these treatments are not effective, heart transplantation may be considered. The prognosis varies depending on the individual and the underlying cause of the DCM.
Disease Severity: The severity of dilated cardiomyopathy (DCM) can vary widely between individuals. Some people may experience mild symptoms or even remain asymptomatic, while others may develop severe heart failure. DCM can lead to significant complications, including arrhythmias, thromboembolisms, and sudden cardiac death. It’s important for affected individuals to be regularly monitored by a healthcare provider to manage symptoms and reduce the risk of complications.
Healthcare Professionals: Disease Ontology ID - DOID:0110454
Pathophysiology: Dilated cardiomyopathy (DCM) is characterized by the enlargement and impaired contraction of the left or both ventricles of the heart. The pathophysiology involves several key factors:

1. **Genetic Mutations**: Mutations in various genes encoding for cytoskeletal, sarcomeric, and nuclear envelope proteins are common, leading to dysfunctional myocardial cells.
2. **Alcohol/Chemicals/Toxins**: Chronic alcohol abuse, exposure to certain chemicals, and toxins can damage myocardial cells, leading to dilation and impaired function.
3. **Autoimmune Factors**: Autoimmune responses can result in the infiltration of inflammatory cells, causing myocardial damage.
4. **Viral Infections**: Some viral infections can lead to myocarditis, which can progress to DCM.
5. **Metabolic Disorders**: Conditions like thyroid disease, diabetes, and nutritional deficiencies can contribute to the development of DCM by affecting myocardial metabolism.

These factors cause alterations in the myocardial structure and function, leading to decreased ejection fraction, increased ventricular volumes, and ultimately heart failure.
Carrier Status: Dilated Cardiomyopathy 1S (DCM1S) is a genetic form of dilated cardiomyopathy. Carrier status typically refers to individuals who have one copy of a mutated gene associated with a specific genetic disorder but do not exhibit symptoms themselves.

For DCM1S, carrying a single mutated gene often predisposes an individual to developing dilated cardiomyopathy, although the severity can vary. If you have specific genetic information about DCM1S, consulting a genetic counselor or healthcare professional can provide personalized insights based on the particular mutation involved.
Mechanism: Dilated cardiomyopathy type 1S (DCM1S) is linked to genetic mutations in the TNNT2 gene, which encodes cardiac troponin T, a key protein in the contractile apparatus of cardiomyocytes. These mutations disrupt the normal function of the troponin complex, impairing force generation and transmission within heart muscle cells. Over time, this biochemical dysfunction leads to weaker heart contractions, ventricular dilation, and a decreased ability to pump blood effectively, culminating in the clinical manifestations of dilated cardiomyopathy. Molecularly, these alterations can cause deficient calcium handling and compromised sarcomeric integrity, contributing to the progressive nature of the disease.
Treatment: Dilated cardiomyopathy (DCM) is a condition characterized by the enlargement and weakening of the heart's ventricles, leading to decreased systolic function. Treatment options include:

1. **Medications:**
- ACE inhibitors or ARBs
- Beta-blockers
- Diuretics
- Aldosterone antagonists
- Anticoagulants (if there's a risk of blood clots)

2. **Lifestyle Changes:**
- Dietary modifications (low-sodium diet)
- Regular, supervised exercise
- Avoiding alcohol and tobacco

3. **Devices:**
- Implantable cardioverter-defibrillator (ICD) for those at risk of sudden cardiac death
- Cardiac resynchronization therapy (CRT) for patients with significant heart rhythm problems

4. **Surgery:**
- In severe cases, a heart transplant may be considered

Regular follow-up with a cardiologist is essential for managing the condition.
Compassionate Use Treatment: For dilated cardiomyopathy (DCM), compassionate use treatments, off-label, or experimental treatments may include:

1. **Compassionate Use Treatments**:
- **Experimental Drugs**: Patients with advanced heart failure due to DCM might access investigational drugs not yet approved by regulatory authorities through compassionate use programs.

2. **Off-label Treatments**:
- **Ivabradine**: Although primarily approved for heart rate reduction in heart failure with reduced ejection fraction, it may be used off-label for heart rate control in DCM.
- **Sildenafil**: Originally for pulmonary hypertension and erectile dysfunction, this drug can be used off-label to improve exercise capacity in DCM by reducing pulmonary pressure.

3. **Experimental Treatments**:
- **Gene Therapy**: Emerging studies are exploring gene therapy to correct specific genetic defects leading to DCM.
- **Cell Therapy**: Stem cell therapy is being investigated for its potential to regenerate damaged myocardium in DCM.
- **Mechanical Circulatory Support Devices**: Implantable devices like left ventricular assist devices (LVADs) are used experimentally or as bridge-to-transplant therapies.

Always consult a healthcare provider for personalized medical advice and information about the availability and suitability of these treatments.
Lifestyle Recommendations: For dilated cardiomyopathy (DCM), the following lifestyle recommendations can help manage the condition:

1. **Dietary Modifications**: Adopting a heart-healthy diet that is low in saturated fats, cholesterol, and sodium can reduce the strain on your heart.
2. **Regular Exercise**: Engaging in moderate exercise, such as walking or cycling, can improve cardiovascular health. It is crucial to consult with a healthcare provider before starting any exercise program.
3. **Weight Management**: Maintaining a healthy weight can reduce the burden on your heart.
4. **Limit Alcohol and Caffeine**: Reducing the intake of alcohol and caffeine can help mitigate symptoms and avoid exacerbating the condition.
5. **Quit Smoking**: Smoking cessation is essential as smoking can exacerbate heart conditions.
6. **Monitor Fluid Intake**: For some individuals, managing fluid intake can help prevent fluid overload, which can strain the heart.
7. **Regular Check-Ups**: Keeping up with regular medical appointments ensures that any changes in your condition can be promptly addressed.
8. **Stress Management**: Strategies such as mindfulness, meditation, and deep-breathing exercises can help manage stress levels, which is beneficial for heart health.

Following these lifestyle recommendations in conjunction with medical treatments prescribed by a healthcare provider can help manage dilated cardiomyopathy effectively.
Medication: Dilated cardiomyopathy (DCM) can be managed with various medications to improve heart function and alleviate symptoms. Common medications include:

1. **ACE Inhibitors** (e.g., enalapril, lisinopril) - help to relax blood vessels and reduce the workload on the heart.
2. **Beta-Blockers** (e.g., carvedilol, metoprolol) - reduce heart rate and blood pressure, improving heart function.
3. **Diuretics** (e.g., furosemide) - help reduce fluid buildup in the body.
4. **Aldosterone Antagonists** (e.g., spironolactone) - help remove excess salt and water from the body while preserving potassium.
5. **Digoxin** - strengthens heart contractions and controls irregular heart rhythms.
6. **Anticoagulants** (e.g., warfarin) - reduce the risk of blood clots.

The selection and combination of medications should be tailored to each patient's condition and overseen by a healthcare provider.
Repurposable Drugs: Repurposable drugs for dilated cardiomyopathy (DCM) include:

1. **Beta-blockers**: Such as carvedilol and metoprolol, which help improve heart function and reduce symptoms.
2. **ACE inhibitors**: Like enalapril and lisinopril, which can decrease blood pressure and reduce strain on the heart.
3. **Angiotensin II receptor blockers (ARBs)**: Such as losartan and valsartan, which are alternatives to ACE inhibitors.
4. **Aldosterone antagonists**: Like spironolactone, which help reduce fluid buildup and improve heart function.
5. **Diuretics**: Such as furosemide, to remove excess fluid from the body and reduce the workload on the heart.
6. **Digoxin**: Which can increase the strength of heart muscle contractions and control heart rate.

Research continues to explore other drugs that might be repurposed for treating DCM effectively. Always consult healthcare professionals for personalized advice.
Metabolites: Dilated cardiomyopathy (DCM) involves the enlargement and impaired contraction of the heart's ventricles. Primary metabolites that can be affected include:

1. **Creatinine**: Elevated levels can indicate kidney impairment, often secondary to cardiac dysfunction in DCM.
2. **Lactate**: Increased levels suggest inadequate oxygen delivery to tissues, which can occur because of the reduced cardiac output in DCM.
3. **B-type natriuretic peptide (BNP)**: Levels are elevated in response to ventricular volume expansion and pressure overload, commonly seen in DCM.
4. **Troponin**: Can be elevated due to myocardial injury in severe cases of DCM.
5. **Amino acids**: Abnormal levels can result from altered metabolic processes in heart failure, a common outcome of DCM.

Monitoring these metabolites can provide insights into the severity and progression of dilated cardiomyopathy as well as the efficacy of treatment strategies.
Nutraceuticals: Currently, there is no specific nutraceutical treatment proven to cure or reverse dilated cardiomyopathy (DCM). Management primarily focuses on conventional medical therapies and lifestyle changes. However, some nutraceuticals are sometimes considered as complementary approaches alongside standard treatment. These can include:

1. **Coenzyme Q10 (CoQ10):** May improve heart function by enhancing energy production in cardiac cells.
2. **Omega-3 Fatty Acids:** Anti-inflammatory properties that can potentially benefit heart health.
3. **L-Carnitine:** Might help in energy metabolism in the heart.
4. **Taurine:** An amino acid thought to support cardiovascular health.

Always consult healthcare professionals before starting any new supplements.
Peptides: Your request seems to be a bit unclear. Generally, peptides can play a role in various aspects of dilated cardiomyopathy (DCM), including diagnostics and potential treatments. Nanotechnology (represented by "nan") is also an emerging field that could offer new therapeutic strategies.

For DCM1S:
- **Peptides**: They may be used in developing biomarkers for early diagnosis or as potential therapeutic agents. Specific peptides could help in modulating heart function or in the inhibition of adverse pathways involved in DCM.
- **Nanotechnology**: Nanoparticles can be engineered to deliver drugs or therapeutic genes directly to the heart tissue, potentially improving the treatment efficacy and reducing side effects.

Advancements in both peptides and nanotechnology hold promise for better management and treatment of dilated cardiomyopathy.